[go: up one dir, main page]

YU17202A - Disperzioni preparati sa sadržajem inhibitora lipaza - Google Patents

Disperzioni preparati sa sadržajem inhibitora lipaza

Info

Publication number
YU17202A
YU17202A YU17202A YUP17202A YU17202A YU 17202 A YU17202 A YU 17202A YU 17202 A YU17202 A YU 17202A YU P17202 A YUP17202 A YU P17202A YU 17202 A YU17202 A YU 17202A
Authority
YU
Yugoslavia
Prior art keywords
formulations containing
lipase inhibitors
dispersion formulations
containing lipase
inhibitor
Prior art date
Application number
YU17202A
Other languages
English (en)
Inventor
Passchier Christiaan De Smidt
Paul Hadvary
Hans Lengsfeld
Thomas Rades
Hans Steffen
Joseph Tardio
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU17202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of YU17202A publication Critical patent/YU17202A/sh
Publication of RS50422B publication Critical patent/RS50422B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Ovaj pronalazak se odnosi na farmaceutske smeše koje sadrže najmanje jedan inhibitor lipaza, prvenstveno inhibitor gastrointestinalnih i pankreasnih lipiza, npr. orlistat, najmanje jednu površinski aktivnu supstancu i najmanje jedan dispergent.[The present invention relates to pharmaceutical compositions comprising at least one inhibitor of lipases, preferably an inhibitor of gastrointestinal and pancreatic lipases, e.g. orlistat, at least one surfactant and at least one dispersant.
YUP-172/02A 1999-09-13 2000-09-11 Disperzioni preparati sa sadržajem inhibitora lipaza RS50422B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99118180 1999-09-13

Publications (2)

Publication Number Publication Date
YU17202A true YU17202A (sh) 2006-01-16
RS50422B RS50422B (sr) 2009-12-31

Family

ID=8238990

Country Status (39)

Country Link
US (3) US20030181512A1 (sh)
EP (1) EP1216025B1 (sh)
JP (1) JP4217016B2 (sh)
KR (1) KR100572434B1 (sh)
CN (1) CN1197551C (sh)
AR (1) AR025587A1 (sh)
AT (1) ATE333866T1 (sh)
AU (1) AU769415B2 (sh)
BR (2) BR0013939A (sh)
CA (1) CA2383916C (sh)
CO (1) CO5180587A1 (sh)
CY (1) CY1106180T1 (sh)
CZ (1) CZ301901B6 (sh)
DE (1) DE60029602T2 (sh)
DK (1) DK1216025T3 (sh)
EG (1) EG24117A (sh)
ES (1) ES2267563T3 (sh)
HK (1) HK1049966A1 (sh)
HR (1) HRP20020205B1 (sh)
HU (1) HU228858B1 (sh)
IL (1) IL148494A0 (sh)
JO (1) JO2386B1 (sh)
MA (1) MA26818A1 (sh)
ME (1) ME00674B (sh)
MX (1) MXPA02002034A (sh)
MY (1) MY130200A (sh)
NO (1) NO331906B1 (sh)
NZ (1) NZ517545A (sh)
PE (1) PE20010595A1 (sh)
PL (1) PL199870B1 (sh)
PT (1) PT1216025E (sh)
RS (1) RS50422B (sh)
RU (1) RU2239428C2 (sh)
SI (1) SI1216025T1 (sh)
TR (1) TR200200606T2 (sh)
TW (1) TWI243060B (sh)
UY (1) UY26338A1 (sh)
WO (1) WO2001019340A1 (sh)
ZA (1) ZA200201518B (sh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100572785B1 (ko) 2000-07-28 2006-04-19 에프. 호프만-라 로슈 아게 신규한 약학 조성물
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
FI20045076L (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
BRPI0607549A2 (pt) * 2005-04-15 2009-09-15 Clarus Therapeutics Inc sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
EP1897558B1 (en) * 2005-06-09 2013-09-04 Norgine BV Solid preparation of 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-one
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
TR200607613A2 (tr) * 2006-12-29 2008-07-21 NOBEL İLAÇ SAN.ve TiC.A.Ş. Lipaz inhibitörü içeren farmasötik formülasyonlar
EP1970051A1 (en) * 2007-03-14 2008-09-17 Merz Pharma GmbH & Co.KGaA Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases
KR101439470B1 (ko) * 2007-05-22 2014-09-16 한미사이언스 주식회사 오를리스타트 및 대변 연화제를 포함하는 비만의 예방 또는치료용 조성물
PL2036575T3 (pl) * 2007-09-12 2011-02-28 Mader S R L Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością
EP2044930A1 (en) * 2007-10-01 2009-04-08 Nestec S.A. Composition for controlling lipase catalyzed reactions
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
KR20100075260A (ko) * 2008-12-24 2010-07-02 주식회사종근당 리파아제 저해제의 부작용 개선을 위한 신규한 약제학적 조성물
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
WO2016166767A1 (en) * 2015-04-14 2016-10-20 Zim Laboratories Limited Pharmaceutical formulation comprising low melting, highly lipophilic drugs
CN106310287B (zh) * 2015-06-25 2019-03-19 山东省药学科学院 新利司他药用组合物及其制备方法
MY196635A (en) * 2018-06-22 2023-04-25 Sime Darby Plantation Intellectual Property Sdn Bhd Method For Reducing Formation of Free Fatty Acids in Plants
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺
CN114983938A (zh) * 2022-05-19 2022-09-02 广东嘉博制药有限公司 一种奥利司他口服复合乳液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
EP0281200B1 (en) * 1987-03-02 1994-01-19 Yamanouchi Europe B.V. Pharmaceutical composition, pharmaceutical granulate and process for their preparation
TW381025B (en) 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
IT1282673B1 (it) 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
JP2001523221A (ja) 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
CZ295567B6 (cs) * 1997-02-05 2005-08-17 F. Hoffmann-La Roche Ag Tetrahydrolipstatin pro výrobu orálního farmaceutického prostředku pro ošetřování typu II diabetes mellitus
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
BR9912979B1 (pt) 1998-08-14 2010-09-21 composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan.
KR20010079635A (ko) 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 리파아제 저해제를 함유하는 약학 조성물
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption

Also Published As

Publication number Publication date
AU769415B2 (en) 2004-01-29
NO20021204L (no) 2002-03-12
DK1216025T3 (da) 2006-10-30
CY1106180T1 (el) 2011-06-08
CN1373656A (zh) 2002-10-09
MEP90808A (en) 2011-12-20
EP1216025A1 (en) 2002-06-26
PE20010595A1 (es) 2001-05-26
RU2239428C2 (ru) 2004-11-10
ATE333866T1 (de) 2006-08-15
WO2001019340A1 (en) 2001-03-22
SI1216025T1 (sl) 2006-12-31
JP4217016B2 (ja) 2009-01-28
CO5180587A1 (es) 2002-07-30
HRP20020205A2 (en) 2004-04-30
ES2267563T3 (es) 2007-03-16
CA2383916A1 (en) 2001-03-22
JP2003509357A (ja) 2003-03-11
KR100572434B1 (ko) 2006-04-18
NO20021204D0 (no) 2002-03-12
HU228858B1 (en) 2013-06-28
IL148494A0 (en) 2002-09-12
AR025587A1 (es) 2002-12-04
ZA200201518B (en) 2003-07-30
CA2383916C (en) 2009-01-20
JO2386B1 (en) 2007-06-17
CN1197551C (zh) 2005-04-20
TR200200606T2 (tr) 2002-07-22
US20040175420A1 (en) 2004-09-09
KR20020063852A (ko) 2002-08-05
RS50422B (sr) 2009-12-31
TWI243060B (en) 2005-11-11
UY26338A1 (es) 2000-10-31
ME00674B (me) 2011-12-20
HUP0202737A2 (hu) 2003-01-28
DE60029602T2 (de) 2007-07-26
DE60029602D1 (de) 2006-09-07
US20110275706A1 (en) 2011-11-10
EG24117A (en) 2008-07-06
BRPI0013939B1 (pt) 2017-07-18
US20030181512A1 (en) 2003-09-25
US8012494B2 (en) 2011-09-06
MY130200A (en) 2007-06-29
MA26818A1 (fr) 2004-12-20
HUP0202737A3 (en) 2005-01-28
BR0013939A (pt) 2002-05-14
AU7286300A (en) 2001-04-17
MXPA02002034A (es) 2002-08-20
CZ20021276A3 (cs) 2003-04-16
PL199870B1 (pl) 2008-11-28
HRP20020205B1 (en) 2011-06-30
HK1049966A1 (en) 2003-06-06
CZ301901B6 (cs) 2010-07-28
NO331906B1 (no) 2012-04-30
PT1216025E (pt) 2006-12-29
PL356174A1 (en) 2004-06-14
EP1216025B1 (en) 2006-07-26
NZ517545A (en) 2003-11-28

Similar Documents

Publication Publication Date Title
JO2386B1 (en) Dispersing compounds containing lipase inhibitors
BG104780A (en) Inhibitors of phospholipase enzymes
GC0000221A (en) Pyrimidinone compounds, processes for their preparation, intermediates useful in their preparation, and pharmaceutical compositions containing them
TR200103216T2 (tr) Pirimidinon bileşimleri
AU2464601A (en) Tricyclic protein kinase inhibitors
AU3328499A (en) Phthalazinone pde iii/iv inhibitors
CR6883A (es) Composiciones farmaceuticas de inhibidores de la potencia de colesteril ester
CA2340052A1 (en) Pharmaceutical compositions containing lipase inhibitors and chitosan
WO2003059296A3 (en) Compositions comprising collagen and metalloprotease inhibitors
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
PT1181035E (pt) Composicoes de ciclosporina substancialmente isentas de oleo
YU78202A (sh) Tečne formulacije
AP1696A (en) Agrochemical formulations comprising ALS inhibitors.
WO2002018954A3 (en) Inhibition of cmv infection and dissemination
WO2001066144A3 (en) Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
PL328916A1 (en) Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs
IL133179A0 (en) Compositions and methods for inhibiting nematocyst discharge
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
MXPA06000987A (es) Derivados de nicotinamida utiles como inhibidores de pde4.
SI1377574T1 (sh)
ECSP003654A (es) Formulaciones de dispersion que contienen inhibidores de lipasa
WO2002048139A3 (en) Oxazolidinone photoaffinity probes
FR2783518B1 (fr) Inhibiteurs de lta4 hydrolase
WO2000076456A3 (en) Modulators of fibrosis
AU2001287673A1 (en) Novel trioxepan compounds